FDA jurisdiction still unchallenged – but industry presses for clarity

The US Food and Drug Administration is moving slowly in drawing regulatory boundaries for CBD businesses. Members of Congress have called for clarity, but the FDA says it has no plans to give cannabis derivatives the green light

Read full article

Download the full news analysis

"*" indicates required fields

Corporate Email*

Company Name*

Name*

Department*

Industry*

Work Telephone*

How did you hear about us?*

Name

This field is for validation purposes and should be left unchanged.

I'm already a subscriber

CannIntelligence

This article was written by one of CannIntelligence’s international correspondents. We currently employ more than 40 reporters around the world to cover individual cannabis and cannabinoid markets. For a full list, please see our Who We Are page.

The global cannabis market is in an opaque regulatory environment that requires professionals to be on top of industry developments to make informed decisions and optimise their strategy.

CannIntelligence provides organisations with leading market and regulatory data analysis to anticipate and understand market developments globally and the impact of regulatory changes to the business.

Stay informed of any legal and market change in the sector that impacts your organisation
Maximise resources by getting market and legal data analysis daily in one place
Make smart decisions by understanding how the regulatory and market landscape evolves
Anticipate risks in your decisions by monitoring regulatory changes that impact your organization

LATEST ALERTS

FDA jurisdiction still unchallenged – but industry presses for clarity

CannIntelligence

Our Key Benefits

Sign up to our newsletter

LATEST ALERTS

Download the full news analysis

CannIntelligence

Our Key Benefits

Thanks for getting in touch with us

Sign up to our newsletter

Start your FREE trial